Nicole Boice

Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023.

Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023.

Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023.

Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023.

Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023.

Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023.

Global Genes is a non-profit organization that connects, empowers, and inspires the rare disease community to become more effective on their own behalf. The non-profit company is based in Aliso Viejo, CA and has subsidiaries in the United States. The company serve more than 400 million people around the globe and nearly one in 10 Americans affected by rare diseases. The organization helps spur innovation, meet essential needs, build capacity and knowledge, and drive progress within and across rare diseases. Global Genes was founded in 2008 and the CEO is Craig Martin.

Global Genes is a non-profit organization that connects, empowers, and inspires the rare disease community to become more effective on their own behalf. The non-profit company is based in Aliso Viejo, CA and has subsidiaries in the United States. The company serve more than 400 million people around the globe and nearly one in 10 Americans affected by rare diseases. The organization helps spur innovation, meet essential needs, build capacity and knowledge, and drive progress within and across rare diseases. Global Genes was founded in 2008 and the CEO is Craig Martin.

Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023.

Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023.

Global Genes is a non-profit organization that connects, empowers, and inspires the rare disease community to become more effective on their own behalf. The non-profit company is based in Aliso Viejo, CA and has subsidiaries in the United States. The company serve more than 400 million people around the globe and nearly one in 10 Americans affected by rare diseases. The organization helps spur innovation, meet essential needs, build capacity and knowledge, and drive progress within and across rare diseases. Global Genes was founded in 2008 and the CEO is Craig Martin.

Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023.

Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023.

Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023.

Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023.

Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023.

Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023.

Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023.

Global Genes is a non-profit organization that connects, empowers, and inspires the rare disease community to become more effective on their own behalf. The non-profit company is based in Aliso Viejo, CA and has subsidiaries in the United States. The company serve more than 400 million people around the globe and nearly one in 10 Americans affected by rare diseases. The organization helps spur innovation, meet essential needs, build capacity and knowledge, and drive progress within and across rare diseases. Global Genes was founded in 2008 and the CEO is Craig Martin.

Global Genes is a non-profit organization that connects, empowers, and inspires the rare disease community to become more effective on their own behalf. The non-profit company is based in Aliso Viejo, CA and has subsidiaries in the United States. The company serve more than 400 million people around the globe and nearly one in 10 Americans affected by rare diseases. The organization helps spur innovation, meet essential needs, build capacity and knowledge, and drive progress within and across rare diseases. Global Genes was founded in 2008 and the CEO is Craig Martin.

Global Genes is a non-profit organization that connects, empowers, and inspires the rare disease community to become more effective on their own behalf. The non-profit company is based in Aliso Viejo, CA and has subsidiaries in the United States. The company serve more than 400 million people around the globe and nearly one in 10 Americans affected by rare diseases. The organization helps spur innovation, meet essential needs, build capacity and knowledge, and drive progress within and across rare diseases. Global Genes was founded in 2008 and the CEO is Craig Martin.